Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 354 participants.

Also called NCT01592240

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 354 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01592240
  • EudraCT 2012-001226-10
Other papers using this trial's data
  • Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia The American journal of cardiology, 2015-05-01 DOI, PubMed 25784512

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01592240. Randomized; triple masking; primary purpose treatment. Start 2012-07 (actual); primary completion 2013-04 (actual). Results posted on 2017-12-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin
Condition
Hypercholesterolemia
Intervention (Drug)
PBO
Intervention (Drug)
200mg PF-04950615 (RN316)
Intervention (Drug)
300mg PF-04950615 (RN316)
Intervention (Drug)
PBO
Intervention (Drug)
PF-04950615
Intervention (Drug)
PF-04950615
Intervention (Drug)
PF-04950615
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct01592240
Content hash
a5a8e137a60897f8d7b3d15825aae804ffd30fdb1f47f1366abfad9b847bf3f0